GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001470612 | Endometrium | EEC | striated muscle tissue development | 74/2168 | 384/18723 | 6.64e-06 | 1.57e-04 | 74 |
GO:00330021 | Endometrium | EEC | muscle cell proliferation | 50/2168 | 248/18723 | 6.08e-05 | 9.21e-04 | 50 |
GO:001072012 | Endometrium | EEC | positive regulation of cell development | 56/2168 | 298/18723 | 1.68e-04 | 2.10e-03 | 56 |
GO:004599512 | Endometrium | EEC | regulation of embryonic development | 18/2168 | 64/18723 | 2.47e-04 | 2.88e-03 | 18 |
GO:00487381 | Endometrium | EEC | cardiac muscle tissue development | 42/2168 | 236/18723 | 3.00e-03 | 2.10e-02 | 42 |
GO:00352651 | Endometrium | EEC | organ growth | 32/2168 | 178/18723 | 7.54e-03 | 4.22e-02 | 32 |
GO:00073698 | Esophagus | ESCC | gastrulation | 115/8552 | 185/18723 | 4.35e-06 | 4.64e-05 | 115 |
GO:001072010 | Esophagus | ESCC | positive regulation of cell development | 172/8552 | 298/18723 | 1.74e-05 | 1.55e-04 | 172 |
GO:00425524 | Esophagus | ESCC | myelination | 85/8552 | 134/18723 | 2.51e-05 | 2.13e-04 | 85 |
GO:00072724 | Esophagus | ESCC | ensheathment of neurons | 86/8552 | 136/18723 | 2.68e-05 | 2.24e-04 | 86 |
GO:00083664 | Esophagus | ESCC | axon ensheathment | 86/8552 | 136/18723 | 2.68e-05 | 2.24e-04 | 86 |
GO:00420636 | Esophagus | ESCC | gliogenesis | 172/8552 | 301/18723 | 3.75e-05 | 3.04e-04 | 172 |
GO:005076710 | Esophagus | ESCC | regulation of neurogenesis | 203/8552 | 364/18723 | 6.10e-05 | 4.68e-04 | 203 |
GO:00507697 | Esophagus | ESCC | positive regulation of neurogenesis | 131/8552 | 225/18723 | 9.71e-05 | 6.90e-04 | 131 |
GO:00100016 | Esophagus | ESCC | glial cell differentiation | 129/8552 | 225/18723 | 2.73e-04 | 1.65e-03 | 129 |
GO:00519606 | Esophagus | ESCC | regulation of nervous system development | 237/8552 | 443/18723 | 5.02e-04 | 2.78e-03 | 237 |
GO:00519625 | Esophagus | ESCC | positive regulation of nervous system development | 149/8552 | 272/18723 | 1.50e-03 | 7.06e-03 | 149 |
GO:006053716 | Esophagus | ESCC | muscle tissue development | 211/8552 | 403/18723 | 3.84e-03 | 1.56e-02 | 211 |
GO:0031641 | Esophagus | ESCC | regulation of myelination | 31/8552 | 47/18723 | 4.01e-03 | 1.62e-02 | 31 |
GO:00330025 | Esophagus | ESCC | muscle cell proliferation | 134/8552 | 248/18723 | 4.80e-03 | 1.86e-02 | 134 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TENM4 | SNV | Missense_Mutation | | c.191N>A | p.Val64Glu | p.V64E | Q6N022 | protein_coding | tolerated_low_confidence(0.1) | probably_damaging(0.988) | TCGA-A1-A0SM-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TENM4 | SNV | Missense_Mutation | | c.2228N>A | p.Thr743Asn | p.T743N | Q6N022 | protein_coding | tolerated(0.15) | benign(0.254) | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
TENM4 | SNV | Missense_Mutation | rs756075933 | c.5105N>A | p.Arg1702His | p.R1702H | Q6N022 | protein_coding | tolerated(0.14) | probably_damaging(0.991) | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
TENM4 | SNV | Missense_Mutation | rs750647178 | c.1855A>G | p.Lys619Glu | p.K619E | Q6N022 | protein_coding | deleterious(0.01) | benign(0.187) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
TENM4 | SNV | Missense_Mutation | | c.6389T>C | p.Ile2130Thr | p.I2130T | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TENM4 | SNV | Missense_Mutation | | c.6748G>T | p.Asp2250Tyr | p.D2250Y | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
TENM4 | SNV | Missense_Mutation | rs750647178 | c.1855A>G | p.Lys619Glu | p.K619E | Q6N022 | protein_coding | deleterious(0.01) | benign(0.187) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TENM4 | SNV | Missense_Mutation | | c.6110C>A | p.Thr2037Lys | p.T2037K | Q6N022 | protein_coding | deleterious(0.02) | benign(0.103) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
TENM4 | SNV | Missense_Mutation | novel | c.1456N>T | p.Pro486Ser | p.P486S | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TENM4 | SNV | Missense_Mutation | rs750647178 | c.1855N>G | p.Lys619Glu | p.K619E | Q6N022 | protein_coding | deleterious(0.01) | benign(0.187) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |